Self-anticoagulation hemoperfusion adsorbent based on chitosan and carrageenan, its preparation method and application

A technology of hemoperfusion and chitosan solution, which is applied in blood circulation treatment, chemical instruments and methods, suction devices, etc., can solve problems such as organ function damage, and achieve the effects of low cost, reduced bleeding risk, and simplified process

Active Publication Date: 2020-03-17
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, (Kang, J.H.et al.An extracorporeal blood-cleansingdevice for sepsis therapy[J].Nat.Med.20,1211–1216(2014).) But this new type of blood purification device also has defects: based on magnetic Nanoparticle hemoperfusion adsorbents may enter the human body along with the blood flow, and may cause additional organ damage in the body during metabolism
However, the combined use of chitosan and carrageenan as a hemoperfusion adsorbent has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Self-anticoagulation hemoperfusion adsorbent based on chitosan and carrageenan, its preparation method and application
  • Self-anticoagulation hemoperfusion adsorbent based on chitosan and carrageenan, its preparation method and application
  • Self-anticoagulation hemoperfusion adsorbent based on chitosan and carrageenan, its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The raw materials used in the present embodiment are calculated in parts by weight. The preparation process of the self-anticoagulation hemoperfusion adsorbent based on chitosan and carrageenan in the present embodiment is as follows:

[0056] (1) 2 parts of acetic acid are added to 98 parts of deionized water to obtain a mass fraction of 2% acetic acid solution; 2 parts of chitosan are added to 98 parts of mass fraction of 2% acetic acid solution and magnetically stirred for 4 hours to obtain mass The fraction is 2% chitosan solution;

[0057] (2) Add 2% chitosan solution into the liquid storage tank of the microsphere preparation device, then operate the gas control valve to apply air pressure to the liquid level in the liquid storage tank through the air compressor, and open the liquid control valve to make 2% The amount of chitosan solution dropped into the sodium hydroxide solution of 0.1mol / L to form chitosan microspheres, after soaking for 4 hours, the chitosan m...

Embodiment 2

[0064] The raw materials used in the present embodiment are calculated in parts by weight. The preparation process of the self-anticoagulation hemoperfusion adsorbent based on chitosan and carrageenan in the present embodiment is as follows:

[0065] (1) 2 parts of acetic acid are added to 98 parts of deionized water to obtain a mass fraction of 2% acetic acid solution; 2 parts of chitosan are added to 98 parts of mass fraction of 2% acetic acid solution and magnetically stirred for 4 hours to obtain mass The fraction is 2% chitosan solution;

[0066] (2) Add 2% chitosan solution into the liquid storage tank of the microsphere preparation device, then operate the gas control valve to apply air pressure to the liquid level in the liquid storage tank through the air compressor, and open the liquid control valve to make 2% The amount of chitosan solution dropped into the sodium hydroxide solution of 0.1mol / L to form chitosan microspheres, after soaking for 4 hours, the chitosan m...

Embodiment 3

[0073] Components, structure, mechanical strength, adsorption performance and anticoagulant performance detection of the self-anticoagulation hemoperfusion adsorbent based on chitosan and carrageenan prepared in Examples 1 and 2:

[0074] 1. Composition and structure detection

[0075] Respectively to the chitosan microspheres and the chitosan-carrageenan hybrid microspheres obtained by the genipin crosslinking obtained in embodiment 1 step (4) and step (7) and embodiment 2 steps (7) (respectively for C 2 -K 1 and C 2 -K 2 ) for Fourier transform infrared spectroscopy detection, the results are as follows image 3 shown; from image 3 can be found in the C 2 -K 1 and C 2 -K 2 In the infrared spectrum at a wavelength of 929cm -1 and 846cm -1 The absorption peaks of 3,6-anhydro-D-galactose and D-galactose-4-sulfate groups appeared respectively, confirming that carrageenan has been successfully introduced into the surface of chitosan microspheres after crosslinking, th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a chitosan-based hemoperfusion adsorbent, which, belongs to the technical field of blood contact materials, the chitosan-based hemoperfusion adsorbent is crosslinked chitosan microspheres, and the invention also discloses an application of the chitosan-based hemoperfusion adsorbent in preparation of a blood perfusion device for sepsis blood purification, wherein the chitosan-based hemoperfusion adsorbent has relatively high endotoxin and bacterium adsorption capacity and good mechanical strength; the adsorbent can efficiently remove endotoxin and pathogenic bacteria such as staphylococcus aureus and Escherichia coli in the blood of a sepsis patient, and is the novel adsorbent which has an application prospect and is specially used for blood purification treatment ofthe sepsis patient.

Description

technical field [0001] The invention relates to the technical field of biological materials / blood contact materials, in particular to a chitosan- and carrageenan-based self-anticoagulant hemoperfusion adsorbent, a preparation method and application thereof. Background technique [0002] Sepsis refers to life-threatening multiple organ failure secondary to infection. It is the leading cause of acute kidney injury in intensive care units, with an annual incidence of more than 31.5 million worldwide and an annual death toll of more than 5.3 million. Traditional treatment of sepsis includes the use of broad-spectrum antibiotics, timely fluid resuscitation, and the application of vasopressors when necessary. However, even though spectrum antibiotics have been widely used in the treatment of sepsis patients, the mortality rate of sepsis patients is still as high as 20-50%. In sepsis, higher blood endotoxin concentration and bacterial load are closely related to the severity of m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): B01J20/24B01J20/28B01J20/30B01J20/32A61M1/36
CPCA61M1/3672A61M1/3679A61M2202/0021B01J20/24B01J20/28004B01J20/28021B01J20/3071B01J20/3225A61M2202/0413
Inventor 苏白海李育霈廖若西邱逦李佳梦韩梅王丽亚熊于勤赵伟锋赵长生
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap